Infiltration Depth is the Most Relevant Risk Factor for Overall Metastases in Early Esophageal Adenocarcinoma.
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
pubmed:
20
12
2019
medline:
29
12
2020
entrez:
20
12
2019
Statut:
ppublish
Résumé
Research in early esophageal adenocarcinoma focused on prediction of lymph node metastases in order to stratify patients for endoscopic treatment instead of esophagectomy. Although distant metastases were described in rates of up to 13% of patients within a follow-up of 3 years, their prediction has been neglected so far. In a secondary analysis, a cohort of 217 patients (53 T1a and 164 T1b) treated by esophagectomy was analyzed for histopathological risk factors. Their ability to predict the combination of lymph node metastases at surgery as well as metachronous locoregional and distant metastases (overall metastatic rate) was assessed by uni- and multivariate logistic regression analysis. Tumor invasion depth was correlated with both lymph node metastases at surgery (τ = 0.141; P = .012), tumor recurrences (τ = 0.152; P = .014), and distant metastases (τ = 0.122; P = 0.04). Multivariate analysis showed an odds ratio of 1.31 (95% CI 1.02-1.67; P = .033) per increasing tumor invasion depth and of 3.5 (95% CI 1.70-6.56; P < .001) for lymphovascular invasion. The pre-planned subgroup analysis in T1b tumors demonstrated an even lower predictive ability of lymphovascular invasion with an odds ratio of 2.5 (95% CI 1.11-5.65; P = 0.028), whereas the predictive effect of sm2 (odds ratio 3.44; 95% CI 1.00-11.9; P = 0.049) and sm3 (odds ratio 3.44; 95% CI 1.00-11.9; P = 0.049) tumor invasion depth was similar. The present report demonstrates the insufficient risk prediction of histopathologic risk factors for the overall metastatic rate.
Sections du résumé
BACKGROUND
Research in early esophageal adenocarcinoma focused on prediction of lymph node metastases in order to stratify patients for endoscopic treatment instead of esophagectomy. Although distant metastases were described in rates of up to 13% of patients within a follow-up of 3 years, their prediction has been neglected so far.
METHODS
In a secondary analysis, a cohort of 217 patients (53 T1a and 164 T1b) treated by esophagectomy was analyzed for histopathological risk factors. Their ability to predict the combination of lymph node metastases at surgery as well as metachronous locoregional and distant metastases (overall metastatic rate) was assessed by uni- and multivariate logistic regression analysis.
RESULTS
Tumor invasion depth was correlated with both lymph node metastases at surgery (τ = 0.141; P = .012), tumor recurrences (τ = 0.152; P = .014), and distant metastases (τ = 0.122; P = 0.04). Multivariate analysis showed an odds ratio of 1.31 (95% CI 1.02-1.67; P = .033) per increasing tumor invasion depth and of 3.5 (95% CI 1.70-6.56; P < .001) for lymphovascular invasion. The pre-planned subgroup analysis in T1b tumors demonstrated an even lower predictive ability of lymphovascular invasion with an odds ratio of 2.5 (95% CI 1.11-5.65; P = 0.028), whereas the predictive effect of sm2 (odds ratio 3.44; 95% CI 1.00-11.9; P = 0.049) and sm3 (odds ratio 3.44; 95% CI 1.00-11.9; P = 0.049) tumor invasion depth was similar.
CONCLUSIONS
The present report demonstrates the insufficient risk prediction of histopathologic risk factors for the overall metastatic rate.
Identifiants
pubmed: 31853591
doi: 10.1007/s00268-019-05291-6
pii: 10.1007/s00268-019-05291-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1192-1199Références
Ann Surg. 2013 Jun;257(6):1032-8
pubmed: 23108117
Surg Endosc. 2016 Sep;30(9):4102-13
pubmed: 27357927
Dis Esophagus. 2019 Nov 13;32(9):
pubmed: 30596900
Virchows Arch. 2005 May;446(5):497-504
pubmed: 15838647
Cancer Epidemiol. 2016 Apr;41:88-95
pubmed: 26851752
Sci Rep. 2018 Sep 18;8(1):14006
pubmed: 30228315
Gastroenterology. 2014 Mar;146(3):652-660.e1
pubmed: 24269290
Am J Clin Pathol. 2017 Nov 2;148(5):416-426
pubmed: 29069275
Cancer. 2016 Jul 15;122(14):2150-7
pubmed: 27142247
Am J Gastroenterol. 2012 Jun;107(6):850-62; quiz 863
pubmed: 22488081
Gastroenterology. 1995 Jun;108(6):1637-49
pubmed: 7768367
Surg Endosc. 2015 Jul;29(7):1888-96
pubmed: 25294553
Ann Surg Oncol. 2010 Sep;17(9):2494-502
pubmed: 20349213
J Natl Cancer Inst. 2014 Jul 16;106(7):
pubmed: 25031273
J Am Coll Surg. 2019 Oct;229(4):366-373
pubmed: 31108196
Ann Surg. 2005 Oct;242(4):566-73; discussion 573-5
pubmed: 16192817
Esophagus. 2017;14(1):37-65
pubmed: 28111536
PLoS One. 2019 Jul 8;14(7):e0219494
pubmed: 31283789
J Am Coll Surg. 2013 Aug;217(2):191-9
pubmed: 23659947
Ann Surg. 2014 Mar;259(3):469-76
pubmed: 24096754
J Thorac Cardiovasc Surg. 2017 Nov;154(5):1787-1793
pubmed: 28867381
Ann Surg. 2011 Feb;253(2):271-8
pubmed: 21119508
Ann Surg. 2011 Nov;254(5):802-7; discussion 807-8
pubmed: 22042472
Dis Esophagus. 2017 Feb 1;30(3):1-11
pubmed: 26952572
Surgery. 2019 Dec;166(6):1033-1040
pubmed: 31493901
J Gastroenterol. 2017 Jul;52(7):800-808
pubmed: 27757547
Clin Gastroenterol Hepatol. 2016 Mar;14(3):369-377.e3
pubmed: 26515637
Ann Surg. 2014 Jan;259(1):96-101
pubmed: 24096772
Endoscopy. 2006 Feb;38(2):149-56
pubmed: 16479422
J Thorac Cardiovasc Surg. 2018 Jul;156(1):406-413.e3
pubmed: 29605441
Br J Surg. 2016 Apr;103(5):544-52
pubmed: 26865114
J Thorac Cardiovasc Surg. 2019 Jan;157(1):397-402.e1
pubmed: 30143376
Ann Surg Oncol. 2018 Jan;25(1):318-325
pubmed: 29147928
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Gastrointest Surg. 2016 Jan;20(1):6-12; discussion 12
pubmed: 26408330
Gastrointest Endosc. 2011 Dec;74(6):1201-6
pubmed: 22000793
World J Gastrointest Endosc. 2016 Dec 16;8(20):763-769
pubmed: 28042390
Nat Genet. 2019 Mar;51(3):506-516
pubmed: 30718927
Ann Thorac Surg. 2017 Dec;104(6):1858-1864
pubmed: 29033014
Ann Surg Oncol. 2013 Jul;20(7):2428-33
pubmed: 23354564